Mercado mundial de anticuerpos monoclonales contra el cáncer: descripción general de la industria

Se espera que el mercado mundial de anticuerpos monoclonales contra el cáncer aumente significativamente durante el período proyectado. Este aumento del mercado se debe en gran medida a la creciente frecuencia de neoplasias malignas sólidas como el cáncer. Otros factores que impulsan la expansión del mercado incluyen la creciente frecuencia de trastornos inmunológicos provocados por antecedentes familiares y la adopción generalizada de estilos de vida poco saludables. La pandemia de COVID-19 también ha contribuido significativamente a la aceleración del crecimiento del mercado.

El informe de mercado de Data Bridge Market Research proporciona detalles de los nuevos desarrollos recientes, la participación de mercado, las tendencias del mercado sobre la base de sus segmentaciones y análisis regionales, el impacto de los actores del mercado, análisis de oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, análisis estratégico del crecimiento del mercado, tamaño del mercado, crecimientos del mercado de categorías, nichos de aplicación y dominio, aprobaciones de productos, lanzamientos de productos, expansiones geográficas, innovaciones tecnológicas en el mercado. Para obtener más información sobre el mercado, comuníquese con el equipo de analistas expertos de Data Bridge Market Research. Nuestro equipo lo ayudará a tomar decisiones de mercado informadas para lograr el crecimiento empresarial.

Tamaño del mercado mundial de anticuerpos monoclonales contra el cáncer

El cambio hacia la medicina personalizada, donde los tratamientos se adaptan a los perfiles genéticos individuales, está impulsando la innovación dentro del mercado global de anticuerpos monoclonales contra el cáncer. A medida que los sistemas de atención médica a nivel mundial priorizan el diagnóstico temprano y el manejo eficaz del cáncer, el papel de los anticuerpos monoclonales ha cobrado mayor importancia. El mercado también se está beneficiando del creciente envejecimiento de la población y de factores relacionados con el estilo de vida, como una mayor exposición a carcinógenos, que han provocado una mayor incidencia del cáncer. Como resultado, Databridge Market Research se sumergió en un análisis exhaustivo del mercado y reveló que el mercado global de anticuerpos monoclonales contra el cáncer está aumentando a una CAGR del 14,00 %. Nuestro análisis detallado pronostica que el mercado está valorado en USD 53,33 mil millones en 2023 y se espera que crezca hasta USD 133,45 mil millones para 2031. Nuestro informe creado meticulosamente, desarrollado a través de una investigación y un análisis exhaustivos, es un documento distinguido que revela datos reveladores sobre el mercado.

Global Cancer Monoclonal Antibodies Market Dynamics

Global Cancer Monoclonal Antibodies Market Growth Drivers

Increase in Cancer Cases

According to the National Cancer Institute (NCI), nearly 20 billion new cancer cases and 9.7 billion cancer-related deaths occurred globally in 2022. These figures are projected to increase dramatically by 2040, with 29.9 billion new cases and 15.3 billion deaths annually. The escalating burden of cancer cases underscores the urgent need for effective cancer treatments, such as monoclonal antibodies, which are increasingly adopted for their precision and efficacy in targeting cancer cells, thereby propelling global cancer monoclonal antibodies market growth.

Advancements in biotechnology

Advancements in biotechnology have revolutionized the development and effectiveness of monoclonal antibodies, making them a cornerstone in modern cancer therapy. For instance Trastuzumab emtansine (Kadcyla), used for HER2-positive breast cancer, has demonstrated improved survival rates and reduced systemic toxicity compared to traditional chemotherapy.

Global Cancer Monoclonal Antibodies Market growth Opportunities

Rising awareness

Governments worldwide are launching campaigns to raise awareness about cancer. For instance, the World Health Organization's "World Cancer Day" campaign, observed every year on February 4th, reaches billions of people globally, spreading awareness about prevention, early detection, and treatment options. As awareness efforts continue to educate the public and healthcare providers about the benefits of early intervention, the demand for effective and targeted therapies like monoclonal antibodies is expected to rise. Growing awareness amplifies the potential for global cancer monoclonal antibodies market.

Increase in ageing population

According to the United Nations, the proportion of the global population aged 65 and more is predicted to climb from 10% in 2022 to 16% in 2050. The generational transition is predicted to increase the incidence of cancer, given the chance of developing cancer increases with age. Consequently, there will be an increased demand for advanced and targeted medicines, such as monoclonal antibodies, to effectively control and treat cancer in an older population.

Global Cancer Monoclonal Antibodies Market growth Challenges

High Cost of Therapy

Monoclonal antibodies are often expensive to develop and administer, leading to high costs for patients and healthcare systems. For instance, treatments like Trastuzumab (Herceptin) can cost tens of thousands of dollars annually. High costs limits accessibility and affordability, creating barriers for widespread adoption and posing a challenge to global cancer monoclonal antibodies market growth.

Lack of technical skills.

A significant challenge for the global cancer monoclonal antibodies market is the shortage of skilled professionals. The development and administration of these therapies require specialized expertise in biotechnology and clinical oncology. For instance, the U.S. Bureau of Labor Statistics reports a projected 13% growth in the demand for medical scientists from 2021 to 2031, indicating a shortage of skilled professionals in this field.

Global Cancer Monoclonal Antibodies Market Restraints

Increased regulations constraining the growth of the global Cancer Monoclonal Antibodies market

The approval process for new therapies is both rigorous and time-consuming, requiring extensive clinical trials and adherence to stringent regulations. For instance, the development of the monoclonal antibody drug Pembrolizumab (Keytruda) involved several phases of clinical trials to demonstrate its safety and efficacy in treating various cancers. The entire process took over a decade from initial research to regulatory approval by the U.S. FDA in 2014. Such lengthy and costly regulatory requirements act as a restraint for the global cancer monoclonal antibodies market.

Global Cancer Monoclonal Antibodies Market Scope and Trends

• New targeted medicines have been developed to treat AML cells with specific genetic alterations and abnormalities. Idhifa (enasidenib), a medication that targets IDH2 mutations, and Venclexta (venetoclax), which targets BCL-2 proteins, have both shown encouraging outcomes in clinical trials.
• Ibrutinib (Imbruvica) and Acalabrutinib (Calquence) have become important in the treatment of Chronic Lymphocytic Leukemia (CLL). Discussed drugs work by inhibiting the BTK enzyme, which is crucial for the survival and proliferation of Chronic Lymphocytic Leukemia (CLL) cells.
• Advances in genomic sequencing are enabling more precise identification of mutations and alterations in solid tumors. Genetic information guides the use of targeted therapies and personalized treatment plans, improving outcomes and reducing unnecessary side effect.
• Combining therapies such as chemotherapy with targeted or immunotherapy is increasingly common. For instance, combining Checkpoint Inhibitors with Chemotherapy is showing promising results in treating epithelial tumors such as NSCLC and bladder cancer.

Global Cancer Monoclonal Antibodies Market Regional Analysis – Market Trends

Key Insights

• The North American cancer monoclonal antibodies market is dominated by the United States and Canada, driven by a high incidence of cancer, advanced healthcare infrastructure, and significant investments in research and development. The region benefits from a robust regulatory environment, with the U.S. FDA’s approval of leading therapies like Pembrolizumab (Keytruda) and Nivolumab (Opdivo) reinforcing its market leadership.
• In Europe, strong healthcare systems, favorable regulatory frameworks, and increasing cancer awareness drive market growth. The European Medicines Agency (EMA) supports the market with its regulatory approvals, and initiatives like Horizon 2020 enhance R&D efforts. The widespread adoption of therapies such as Trastuzumab (Herceptin) and Bevacizumab (Avastin) highlights the region’s key role in the global market.
• The Asia-Pacific region, led by China, Japan, and India, is experiencing rapid growth in the cancer monoclonal antibodies market, driven by significant factors such as expanding healthcare infrastructure, rising cancer incidence, and increasing healthcare expenditure. In China, the approval of new therapies like Sintilimab (a PD-1 inhibitor) underscores the country’s growing market for advanced cancer treatments. Additionally, India’s increasing healthcare investments and growing pharmaceutical sector are contributing to the market’s expansion.
• The cancer monoclonal antibodies market in the Middle East and Africa is expanding, with South Africa, Saudi Arabia, and the UAE at the forefront. In South Africa, initiatives such as the South African National Cancer Registry are improving cancer detection and treatment access. Saudi Arabia’s Vision 2030 plan includes substantial investments in healthcare infrastructure and cancer care, leading to the development of advanced oncology centers such as King Fahd Medical City.

Global Cancer Monoclonal Antibodies Market Leading Players

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Fresenius Kabi AG (Germany)
• Akorn Incorporated (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)

Global Cancer Monoclonal Antibodies Market Recent Developments

• In February, 2024 Scientists at Tohoku University develop a new monoclonal antibody to treat HER2-positive breast cancer.
• En abril de 2024, la aprobación de Elahere por parte de la Administración de Alimentos y Medicamentos de EE. UU. amplía las opciones de tratamiento para los cánceres de ovario resistentes al platino cuyos tumores producen una cantidad excesiva de una proteína llamada FR-α.
• Investigadores del Hospital de Niños de Filadelfia (CHOP) y de la Facultad de Medicina Perelman de la Universidad de Pensilvania (Penn) descubrieron que el empalme de genes dentro de las células cancerosas podría generar grandes variaciones en los niveles de la proteína CD20, lo que hace que las terapias sean ineficaces.
• En agosto de 2024, GlycoNex, una empresa de biotecnología en etapa clínica centrada en el desarrollo de medicamentos contra el cáncer dirigidos a los glicanos, informó la finalización exitosa de un ensayo clínico de fase 1 para su biosimilar de denosumab, SPD8, desarrollado en conjunto con la empresa Mitsubishi Gas Chemical, Inc.

SKU-53945